Kaskela Law investigates Humana Inc. over alleged securities fraud

1 min read | Published on 23 Jul 2026, 06:31 PM |Updated on 23 Jul 2026, 06:31 PM

Reviewed by

Ashish TScanX News Team

Key Highlights

Kaskela Law LLC is investigating Humana Inc. for potential federal securities law violations and fiduciary breaches by its board of directors. The probe follows a complaint alleging false statements about the Medicare Advantage business between July 27, 2022, and October 1, 2024, which reportedly led to stock price declines. Investors who bought shares before July 1, 2023, are advised to contact the firm.

*this image is generated using AI for illustrative purposes only.

Kaskela Law LLC is investigating Humana Inc. on behalf of the company’s long-term investors to determine if federal securities laws were violated. The investigation focuses on whether members of Humana’s board of directors breached their fiduciary duties in connection with alleged misconduct involving the company’s core Medicare Advantage business.

A federal securities fraud complaint was recently filed against Humana on behalf of certain investors who purchased shares between July 27, 2022, and October 1, 2024. According to the complaint, Humana and certain senior executive officers issued a series of materially false and misleading statements to investors during this period.

The complaint details that the truth regarding Humana’s increased utilization began to emerge in June 2023. This revelation caused a series of stock price declines in the latter half of 2023 and during fiscal 2024.

Kaskela Law LLC is examining whether the board's actions or inactions contributed to the alleged misleading disclosures. The firm exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation on a contingent basis.

Current Humana shareholders who purchased or acquired their HUM shares prior to July 1, 2023, are encouraged to contact Kaskela Law LLC for additional information about the investigation and their legal rights. The firm can be reached by phone at (484) 229 – 0750 or via email at abell@kaskelalaw.com .

Key Dates	Details
Wrongdoing Period	July 27, 2022 to October 1, 2024
Truth Emerged	June 2023
Shareholder Deadline	Purchased prior to July 1, 2023

How will the ongoing investigation impact Humana's strategic focus on its Medicare Advantage business?

What potential financial penalties or settlements could Humana face if the securities fraud allegations are proven?

Will the investigation lead to changes in Humana's board composition or executive leadership?

TD Cowen, Truist raise Humana price targets, maintain Hold

0 min read | Published on 14 Jul 2026, 09:08 PM |Updated on 15 Jul 2026, 12:16 AM

Reviewed by

Radhika SScanX News Team

Add as a preferred
source on Google

Key Highlights

TD Cowen analyst Ryan Langston and Truist Securities analyst David Macdonald maintained Hold ratings on Humana while raising price targets to $350 and $415, respectively.

*this image is generated using AI for illustrative purposes only.

TD Cowen analyst Ryan Langston and Truist Securities analyst David Macdonald have maintained Hold ratings on Humana (NYSE: HUM) while raising their respective price targets. The revised targets reflect updated valuation perspectives on the healthcare company's stock, with TD Cowen increasing its target to $350 from $211 and Truist raising its target to $415 from $320.

Rating and Price Action

The decision to retain Hold ratings suggests that while the stocks' potential upside has been reassessed, the risk-reward profiles remain balanced at current levels. The increases in price targets indicate a shift in the firms' fair value estimates for the company.